Post-earnings recap
Reported
Wed, Aug 8, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a smaller-than-expected loss per share, which contributed to a positive stock reaction, with shares rising by 5.18%. The company did not provide revenue figures or future guidance, but management's optimistic tone suggests confidence in their ongoing projects. Investors may view the EPS beat as a sign of operational efficiency.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.11 | N/A | +29.99% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's performance, particularly in terms of EPS. They emphasized their commitment to ongoing clinical development.
We are pleased with our progress this quarter.
Our focus remains on advancing our clinical programs.